Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2003
12/23/2003CA2267800C Tricyclic compounds having activity as ras-fpt inhibitors
12/23/2003CA2233178C (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors
12/23/2003CA2149207C Compounds that inhibit t cell proliferation and methods using the same
12/23/2003CA2116387C Oxazolidinedione derivatives, their production and use
12/19/2003WO2002101076A2 Methods for targeted expression of therapeutic nucleic acid
12/19/2003CA2460095A1 Methods for targeted expression of therapeutic nucleic acid
12/18/2003WO2003104807A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003WO2003104467A1 Means and methods for the production of adenovirus vectors
12/18/2003WO2003104459A1 Fcyriia transgenic animal model for autoimmune disease
12/18/2003WO2003104443A2 Hair follicle mesenchymal stem cells and use thereof
12/18/2003WO2003104426A2 Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof
12/18/2003WO2003104268A1 Par-2-activating peptide derivative and pharmaceutical composition using the same
12/18/2003WO2003104260A2 Pharmaceutical formulation
12/18/2003WO2003104250A1 New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
12/18/2003WO2003104235A1 Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]pyrazines and decahydropyrazino[1,2-a]azepines
12/18/2003WO2003104230A1 Bicyclic pyrimidine derivatives
12/18/2003WO2003104229A1 Novel fused imidazole derivative
12/18/2003WO2003104226A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/18/2003WO2003104225A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/18/2003WO2003104223A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003WO2003104222A1 Bisindolyl-maleimid derivatives as kinase inhibitors
12/18/2003WO2003104221A1 Inhibitors of the gpib -vwf interaction, their preparation and use
12/18/2003WO2003104219A1 Nf-kb inhibitors
12/18/2003WO2003104218A1 Nf-:b inhibitors
12/18/2003WO2003104208A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
12/18/2003WO2003104207A2 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
12/18/2003WO2003104205A1 Aryloximes
12/18/2003WO2003104204A1 Pyridazine derivatives
12/18/2003WO2003104203A1 Therapeutic molecules and methods-1
12/18/2003WO2003104198A1 Chemokine receptor antagonist
12/18/2003WO2003104197A1 Polymorphic form xvi of fexofenadine hydrochloride
12/18/2003WO2003104195A1 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003WO2003104193A1 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
12/18/2003WO2003104178A1 Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
12/18/2003WO2003103772A1 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
12/18/2003WO2003103771A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
12/18/2003WO2003103721A1 Gene therapeutic for cerebrovascular disorders
12/18/2003WO2003103715A1 Modified byrodin 1 with reduced immunogenicity
12/18/2003WO2003103712A1 Combinations comprising epothilones and pharmaceutical uses thereof
12/18/2003WO2003103705A1 Metalloproteinase inhibitors
12/18/2003WO2003103701A1 Compositions and methods for treating diabetes
12/18/2003WO2003103695A1 Novel therapeutic use of polypodium extracts
12/18/2003WO2003103687A1 Liquid formulation of decitabine and use of the same
12/18/2003WO2003103676A2 Method of treating cancer using kinase inhibitors
12/18/2003WO2003103671A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/18/2003WO2003103667A1 Inhibitors against complex ii of electron transport system
12/18/2003WO2003103664A1 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
12/18/2003WO2003103663A2 Substituted pyrrolines as kinase inhibitors
12/18/2003WO2003103661A1 SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
12/18/2003WO2003103660A1 Substituted phenylsulfonamide inhibitors of beta amyloid production
12/18/2003WO2003103659A1 Therapeutic agent for overactive bladder
12/18/2003WO2003103658A1 Immunity-related protein kinase inhibitors
12/18/2003WO2003103656A1 O-substituted hydroxyaryl derivatives
12/18/2003WO2003103654A1 NF-kappaB ACTIVATION INHIBITORS
12/18/2003WO2003103640A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
12/18/2003WO2003103608A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor
12/18/2003WO2003103604A2 Gamma lactams as prostaglandin agonists and use thereof
12/18/2003WO2003103590A2 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
12/18/2003WO2003103584A2 Ether substituted imidazopyridines
12/18/2003WO2003103581A2 Compositions and methods for liver growth and liver protection
12/18/2003WO2003103577A2 Novel recombinant anticoagulant proteins
12/18/2003WO2003103575A2 Compounds, compositions, and methods
12/18/2003WO2003103569A2 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
12/18/2003WO2003103478A2 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
12/18/2003WO2003103475A2 Prevention and reduction of blood loss
12/18/2003WO2003097052A3 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
12/18/2003WO2003087087A3 Heterocyclic compounds and their use as modulators of p38 map kinase
12/18/2003WO2003082817A3 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/18/2003WO2003082192A3 Certain pharmaceutically useful substituted aminoalkyl heterocycles
12/18/2003WO2003079991A3 Method for administration of growth hormone via pulmonary delivery
12/18/2003WO2003074504A3 Process and intermediates for preparing phenylthiomethyl-thiazoles or oxazoles
12/18/2003WO2003074500A3 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
12/18/2003WO2003074467A3 Urea derivatives as hiv aspartyl protease inhibitors
12/18/2003WO2003070701B1 Syntheses of quinazolinones
12/18/2003WO2003068207A3 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
12/18/2003WO2003066630A3 Quinolinone derivatives for treating cell proliferation related disorders
12/18/2003WO2003066593A3 Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl )-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-methyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
12/18/2003WO2003061704A3 Combination therapy for the treatment of bacterial infections
12/18/2003WO2003053431A3 Pharmaceutical compositions based on azetidine derivatives
12/18/2003WO2003051917A3 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/18/2003WO2003051306A3 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
12/18/2003WO2003050108A8 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
12/18/2003WO2003042405A3 Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
12/18/2003WO2003040309A3 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
12/18/2003WO2003039440A3 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
12/18/2003WO2003031606A3 Crystal structure of an aurora kinase catalytic domain, and use thereof
12/18/2003WO2003027234A3 Small organic molecule regulators of cell proliferation
12/18/2003WO2003022804A9 Method for the preparation of crystalline tetrahydrobenzothiepines
12/18/2003WO2003022302A3 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
12/18/2003WO2003015773A3 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
12/18/2003WO2003014342A3 Identification of a dna variant associated with adult type hypolactasia
12/18/2003WO2003013536A3 Methods for treatment of cancer using irinotecan based on ugt1a1
12/18/2003WO2003009817B1 Stable lyophilized pharmaceutical formulation of igg antibodies
12/18/2003WO2003000864A8 Nucleic acid-associated proteins
12/18/2003WO2002101049A3 Interleukin-18 mutants, their production and use
12/18/2003WO2002090375A3 Liver x receptor agonists
12/18/2003WO2002085305A3 Compositions and methods for inducing cancer cell death
12/18/2003WO2002067941A8 Combination comprising a signal transduction inhibitor and an epothilone derivative
12/18/2003WO2002060871A8 Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
12/18/2003WO2002058723A3 Chemokines as adjuvants of immune response
1 ... 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 ... 1564